{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Patients who cross over to SVdX or SdX after IRC-confirmed PD, will have an End of Vd Treatment Visit and a C1D1 Visit for', 'SVdX or SdX Treatment (Table 3). At the discretion of the Investigator, these visits may be combined. After the C1D1 Visit for', 'SVdX or SdX Treatment, SVdX and SdX patients will follow the schedule in Table 2.', 'SVdX (Table 6) and SdX (Table 7) patients will undergo MM evaluations every 5 weeks.', 'Table 3:', 'Unique Visits Required for Crossover to SVdX or SdX: Separate OR Combined Visits', 'Separate Visits', 'Combined Visits', 'End of Vd Treatment Visit', 'Separate C1D1 Visit for SVdX or SdX', 'End of Vd Treatment Visit and C1D1 Visit', '(within 14 days after IRC PD', 'Treatment', 'for SVdX or SdX Treatment Combined', 'confirmationb)', '(>5 days and 14 days after IRC PD', '(>5 days and <14 days after IRC PD', 'confirmation)', 'confirmation)', 'Informed consent for SVdX or SdX', 'Informed consent for SVdX or SdX treatmentd', 'treatmentd', 'All assessments for EoT Visit in', 'MM disease assessments (SPEP, UPEP,', 'All assessments for EoT Visit in Table 2,', 'Table 2, including MM disease', 'serum protein and urine protein', 'including MM disease assessments (SPEP,', 'assessments (SPEP, UPEP, serum', 'protein and urine protein', 'immunofixation, quantitative Ig, serum FLC,', 'UPEP, serum protein and urine protein', 'immunofixation, quantitative Ig, serum', 'and clinical plasmacytoma assessment)', 'immunofixation, quantitative Ig, serum FLC,', 'FLC, and clinical plasmacytoma', 'and clinical plasmacytoma assessment)', 'assessment)', 'BSA', 'BSA', 'Vital signs', 'Vital signs', 'Nutritional consultation', 'Nutritional consultation', 'Abbreviations: BSA = body surface area; EoT = end of treatment; FLC = free light chain; Ig = immunoglobulin; IRC = Independent Review Committee; MM = multiple', 'myeloma;', 'PD', '=', 'progressive', 'disease; SdX = selinexor plus low-dose dexamethasone treatment after crossover; SPEP = serum protein electrophoresis; SVd = selinexor', 'plus bortezomib plus low-dose dexamethasone; SVdX = SVd treatment after crossover; UPEP = urine protein electrophoresis; Vd = bortezomib plus', 'lowdose- dexamethasone.', 'a The End of Vd Treatment Visit and the C1D1 Visit for SVdX or SdX treatment may be combined at the discretion of the Investigator.', 'b PD confirmation date is the date the IRC informs the site that PD has been confirmed.', 'c', 'If the C1D1 Visit for SVdX/SdX Treatment is a separate visit from the End of Vd Treatment Visit, the clinical and laboratory assessments performed at the End', 'of Vd Treatment Visit do not need to be repeated and the symptom-directed physical examination listed for C1D1 in Table 2 does not need to be performed.', 'However, MM disease assessments and the nutritional consultation must be performed on C1D1.', 'd Informed consent for SVdX/SdX treatment must be signed before conducting any study-specific procedures for SVdX/SdX.', 'Confidential', 'Page 28', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '3.1.', 'Schedules of Visits for In-clinic Dosing and MM Evaluations', 'Table 4:', 'SVd Arm: Schedule of Visits for In-clinic Dosing and MM Evaluations', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5', 'Day', 'Cycles', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', '32', '33', '34', '35', '1', 'X', 'C', 'C', 'X', '2', 'C', 'C', 'C', 'M*', '3', 'C', 'C', 'X', 'C', '4', 'C', 'C', 'X', '5', 'C', 'C', 'C', 'M*', '6', 'C', 'C', 'X', 'C', '7', 'C', 'C', 'X', '>8', 'C', 'X', 'C', 'C', 'Abbreviations: X = Visit for in-clinic dosing and MM disease assessment; C = Visit for in-clinic dosing only; M = Visit for MM disease assessments only; MM = multiple', 'myeloma; SVd = selinexor plus bortezomib plus low-dose dexamethasone.', '*Note: On C2D29 and C5D29, selinexor and dexamethasone dosing should be performed in the clinic during MM disease assessment visits.', 'Table 5:', 'Vd Arm: Schedule of Visits for In-clinic Dosing and MM Evaluations', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5', 'Day', 'Cycles', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', '32', '33', '34', '35', '1', 'C', 'C', 'C', '2', 'C', 'C', 'C', '3', 'C', 'C', 'C', '4', 'C', 'C', 'C', '5', 'C', 'C', 'C', '6', 'C', 'C', 'C', '7', 'C', 'C', 'C', '8', 'C', 'C', 'C', '9', 'C', 'C', '10', 'C', 'X', 'C', 'C', 'M', '>11', 'C', 'C', 'C', 'Abbreviations: X = Visit for in-clinic dosing and MM disease assessment; C = Visit for in-clinic dosing only; M = Visit for MM disease assessments only; MM = multiple', 'myeloma; Vd = bortezomib plus low-dose dexamethasone.', 'Confidential', 'Page 29', 'Version 4.0']\n\n###\n\n", "completion": "END"}